GlaxoSmithKline Discontinues Flovent Rotadisk
This article was originally published in The Pink Sheet Daily
Executive Summary
The company cites manufacturing issues and low sales in deciding to discontinue the fluticasone dosage form. The asthma product will continue to be available as inhalation aerosol.
You may also be interested in...
GlaxoSmithKline Flovent HFA Clears FDA
The CFC-free version of Flovent is approved for asthma in patients 12 years and older. The drug is the second HFA nasal steroid available.
Pink Sheet Podcast: Dsuvia Warning Letter, Refuse-To-File Impact, CDER’s COVID Workload
Pink Sheet reporters and editor discuss the issues surrounding an FDA warning letter on Dsuvia promotion, an expected jump in CDER coronavirus-related workload, and a study of refuse-to-file actions.
Pink Sheet Podcast: COVID-19 variants and vaccine trial dropouts, Aducanumab, User Fee Goal Changes
Pink Sheet reporters and editor discuss the latest coronavirus vaccine news, CMS’ effect on the future of aducanumab, as well as new assessment goals for PDUFA VII.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: